Jiangsu Nanfang Medical Co., Ltd. (SHA:603880)
China · Delayed Price · Currency is CNY 7.74
+0.03 (0.39%)
May 8, 2026, 3:00 PM CST
Jiangsu Nanfang Medical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 584.68 | 600.51 | 602.01 | 599.66 | 544.78 | 523.74 |
Other Revenue | - | - | 0.6 | 0.43 | 0.59 | 3.7 |
| 584.68 | 600.51 | 602.62 | 600.1 | 545.37 | 527.44 | |
Revenue Growth (YoY) | -7.83% | -0.35% | 0.42% | 10.04% | 3.40% | -50.82% |
Cost of Revenue | 561.83 | 577.08 | 631.53 | 566.33 | 477.73 | 432.92 |
Gross Profit | 22.85 | 23.43 | -28.91 | 33.76 | 67.63 | 94.52 |
Selling, General & Admin | 49.3 | 50.88 | 94.79 | 59.95 | 56.17 | 70.97 |
Research & Development | 26.71 | 28.61 | 28.72 | 28.18 | 27.73 | 30.62 |
Other Operating Expenses | 3.54 | 3.84 | 4.22 | 6.52 | 5.66 | 4.35 |
Operating Expenses | 79.54 | 83.32 | 111.2 | 124.54 | 93.99 | 110.53 |
Operating Income | -56.69 | -59.89 | -140.11 | -90.77 | -26.36 | -16.01 |
Interest Expense | - | - | -26.43 | -23.19 | -20.18 | -11.8 |
Interest & Investment Income | 9.52 | 9.52 | 8.69 | 9.15 | 9.38 | 8.8 |
Earnings From Equity Investments | 0.05 | - | - | - | - | - |
Currency Exchange Gain (Loss) | - | - | -1.04 | 0.58 | 5.85 | -3.76 |
Other Non Operating Income (Expenses) | -34.09 | -33.6 | -0.7 | -9.33 | -1.53 | -6.67 |
EBT Excluding Unusual Items | -81.21 | -83.97 | -159.59 | -113.56 | -32.85 | -29.43 |
Gain (Loss) on Sale of Investments | -0.04 | -0.04 | - | 1.3 | 1.23 | - |
Gain (Loss) on Sale of Assets | - | - | -0.21 | -4.29 | -0.03 | 0.05 |
Asset Writedown | -9.31 | -9.14 | -38.4 | -34.17 | - | -2.48 |
Other Unusual Items | - | - | -2.66 | 2.2 | 2.31 | 1.17 |
Pretax Income | -90.56 | -93.14 | -200.86 | -148.52 | -29.34 | -30.69 |
Income Tax Expense | 7.63 | 7.97 | -10.36 | -1.23 | -14.41 | -7.65 |
Earnings From Continuing Operations | -98.2 | -101.12 | -190.5 | -147.29 | -14.94 | -23.04 |
Minority Interest in Earnings | -0.69 | -0.59 | -0.17 | -0.13 | 0.29 | 0.28 |
Net Income | -98.88 | -101.71 | -190.67 | -147.42 | -14.65 | -22.76 |
Net Income to Common | -98.88 | -101.71 | -190.67 | -147.42 | -14.65 | -22.76 |
Shares Outstanding (Basic) | 288 | 291 | 289 | 289 | 293 | 285 |
Shares Outstanding (Diluted) | 288 | 291 | 293 | 289 | 293 | 285 |
Shares Change (YoY) | -0.52% | -0.93% | 1.48% | -1.34% | 2.97% | -0.60% |
EPS (Basic) | -0.34 | -0.35 | -0.66 | -0.51 | -0.05 | -0.08 |
EPS (Diluted) | -0.34 | -0.35 | -0.66 | -0.51 | -0.05 | -0.08 |
Free Cash Flow | 67.28 | 34.53 | 30.92 | -50.65 | -114.88 | -296.01 |
Free Cash Flow Per Share | 0.23 | 0.12 | 0.10 | -0.17 | -0.39 | -1.04 |
Gross Margin | 3.91% | 3.90% | -4.80% | 5.63% | 12.40% | 17.92% |
Operating Margin | -9.70% | -9.97% | -23.25% | -15.13% | -4.83% | -3.03% |
Profit Margin | -16.91% | -16.94% | -31.64% | -24.57% | -2.69% | -4.32% |
Free Cash Flow Margin | 11.51% | 5.75% | 5.13% | -8.44% | -21.07% | -56.12% |
EBITDA | -13.13 | -15.03 | -90.07 | -36.5 | 14.86 | 12.87 |
EBITDA Margin | -2.25% | -2.50% | -14.95% | -6.08% | 2.73% | 2.44% |
D&A For EBITDA | 43.56 | 44.86 | 50.04 | 54.27 | 41.22 | 28.88 |
EBIT | -56.69 | -59.89 | -140.11 | -90.77 | -26.36 | -16.01 |
EBIT Margin | -9.70% | -9.97% | -23.25% | -15.13% | -4.83% | -3.03% |
Revenue as Reported | - | - | 602.62 | 600.1 | 545.37 | 527.44 |
Advertising Expenses | - | - | 1.97 | 1.09 | 0.67 | 0.48 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.